Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. - Wikidata - wikimedia - TriplyDB

Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials.

Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials.

http://www.wikidata.org/entity/Q46851619

about

Evolutionary landscape of the Mycobacterium tuberculosis complex from the viewpoint of PhoPR: implications for virulence regulation and application to vaccine development Recent advances in the development of vaccines for tuberculosis Recent advances towards tuberculosis control: vaccines and biomarkers Host immune responses to mycobacterial antigens and their implications for the development of a vaccine to control tuberculosis ESX-1-induced apoptosis during mycobacterial infection: to be or not to be, that is the question Bacterial genome engineering and synthetic biology: combating pathogens Current efforts and future prospects in the development of live mycobacteria as vaccines Tuberculosis vaccines: barriers and prospects on the quest for a transformative tool Novel vaccination strategies against tuberculosis.The PhoP-dependent ncRNA Mcr7 modulates the TAT secretion system in Mycobacterium tuberculosis.Novel vaccination approaches to prevent tuberculosis in children bioA mutant of Mycobacterium tuberculosis shows severe growth defect and imparts protection against tuberculosis in guinea pigs.Bim is a crucial regulator of apoptosis induced by Mycobacterium tuberculosis.Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.A specific polymorphism in Mycobacterium tuberculosis H37Rv causes differential ESAT-6 expression and identifies WhiB6 as a novel ESX-1 component TB Vaccines: The (Human) Challenge Ahead.DNA consensus sequence motif for binding response regulator PhoP, a virulence regulator of Mycobacterium tuberculosis.Understanding and overcoming the barriers to T cell-mediated immunity against tuberculosis Vaccine against tuberculosis: what's new?Immunology studies in non-human primate models of tuberculosis Mycobacterium tuberculosis requires the ECF sigma factor SigE to arrest phagosome maturation.Animal models of tuberculosis: Guinea pigs.Novel GMO-Based Vaccines against Tuberculosis: State of the Art and Biosafety Considerations The Carbonic Anhydrase Inhibitor Ethoxzolamide Inhibits the Mycobacterium tuberculosis PhoPR Regulon and Esx-1 Secretion and Attenuates Virulence.Granzyme A Is Expressed in Mouse Lungs during Mycobacterium tuberculosis Infection but Does Not Contribute to Protection In Vivo Protection by novel vaccine candidates, Mycobacterium tuberculosis ΔmosR and ΔechA7, against challenge with a Mycobacterium tuberculosis Beijing strain.A High-Throughput Assay for Developing Inhibitors of PhoP, a Virulence Factor of Mycobacterium tuberculosis T Cell Responses against Mycobacterial Lipids and Proteins Are Poorly Correlated in South African Adolescents.Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice.Structural basis of DNA sequence recognition by the response regulator PhoP in Mycobacterium tuberculosis BCG and New Preventive Tuberculosis Vaccines: Implications for Healthcare Workers.Current status of new tuberculosis vaccine in children.Balancing Trained Immunity with Persistent Immune Activation and the Risk of Simian Immunodeficiency Virus Infection in Infant Macaques Vaccinated with Attenuated Mycobacterium tuberculosis or Mycobacterium bovis BCG Vaccine.The BCG replacement vaccine VPM1002: from drawing board to clinical trial.Aerosol immunisation for TB: matching route of vaccination to route of infection Release of mycobacterial antigens.Animal models in tuberculosis research - where is the beef?Mycobacterium tuberculosis virulence: insights and impact on vaccine development.Mycobacterium tuberculosis sigE mutant ST28 used as a vaccine induces protective immunity in the guinea pig model.

P2860

Q26778612-B85BD938-8B4C-4CBA-AAB4-446CEB1CE491 Q26796440-C575A25D-9425-42D9-B619-26ACBADCAE97 Q26859739-328F0A30-1B11-43B7-9643-D04E253C2C34 Q26863391-EA9904E2-B9EA-4976-A3B6-B858B5E63E82 Q27011691-CDC5346C-388F-4733-8C1E-04FE59BB10AC Q28066540-6EF240A5-786C-40D5-AB11-47833B71B122 Q28087077-99F758E9-8920-4D28-9A49-8E14480E0437 Q28390218-71244D9B-1B34-4B94-8771-566B598BBD1E Q30363188-73DAC99C-58D4-4CFE-9C54-9960576F040D Q31161909-909A9C7D-9801-436F-B717-0FF553CEA72A Q33801426-7761081F-0FAF-4F03-B008-F3C73005D0A1 Q33848397-9EEF4275-CAFF-48F4-8D0D-1102B9BD401B Q34007843-02BD6827-1289-4809-8870-5F2DB03F1EA5 Q34055234-32DB1C77-29A3-4140-8AD5-9757485671E2 Q34059004-20406965-C540-44EC-BF3E-7BC36E8FA062 Q34676075-C46207AF-BA4D-4E1C-9D83-4BD05455F6C6 Q34822262-6A1151BA-83E9-408E-A320-1FE2D19B0D24 Q35039934-DDAAAF2C-7063-4A9A-9E1D-17F7AB9A964E Q35101472-ADF37374-2B10-4617-8BFD-CABE5C4A0ADD Q35116998-ABDA5885-6BAE-49E1-9CAC-B1BC31F67622 Q35288521-98597355-25C8-4BEF-AB93-2BC0F17C1CB4 Q35663870-4659D8AB-1BE8-4788-AB09-913493BB9C8D Q35826779-F5427EB6-AB4A-47A0-93A2-5FB285C87BA0 Q35859939-09F1C05D-3295-4BF0-B0F2-5900E48F7B3E Q35982800-893F1B81-E189-4068-A082-20266ADAC35A Q36145657-13C947F4-17DA-4E66-A651-B8C408422032 Q36164838-6E99128B-1A13-441B-AB94-D9D258B665C2 Q36260275-C5162667-F136-47F4-80E5-073169E20607 Q36369598-B51B9830-AA03-401E-9903-248A5D0BDD98 Q36504099-39F1D8A4-40E0-4B67-B35C-979BADF70826 Q36799521-FC8AE23B-FB45-4A58-842C-3765491BF166 Q36838289-C152D54E-565D-4ABC-A04A-61E11615AD89 Q37130796-7AB8E036-208B-4BDE-9391-D76EFC976357 Q37563616-35959E07-553A-46FD-A9A8-238682EF69AD Q38202181-C7B6A7F9-1862-49FF-A3F1-B8CEAEC06444 Q38338183-5784242C-18B3-454B-8333-CFCBD483C1C4 Q38363789-4DF7C129-715F-452C-B44E-87CD88057628 Q38527417-A1C980A5-3155-46A1-931B-1CA5A1529AE7 Q38539493-A328CDB2-CA88-46FA-B0C0-4FBE6DA9C8E4 Q38627716-1C9F8C87-7DBB-4BA0-8A3B-2AEE80E27424

P2860

Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials.

http://www.wikidata.org/entity/Q46851619

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Construction, characterization ...... cine to enter clinical trials.

@en

Construction, characterization ...... cine to enter clinical trials.

@nl

type

label

Construction, characterization ...... cine to enter clinical trials.

@en

Construction, characterization ...... cine to enter clinical trials.

@nl

prefLabel

Construction, characterization ...... cine to enter clinical trials.

@en

Construction, characterization ...... cine to enter clinical trials.

@nl

P1433

Q46851619-E7D9D335-86D9-4CFA-B1D2-35E84C68070C

P1476

Q46851619-627A78B2-8139-497D-B02D-4008F0B2543B

P2093

Q46851619-057E29E7-5DA5-4F29-996C-467E1F324156

Q46851619-1B585ADB-D627-41B6-B6B9-406A1CA6C20B

Q46851619-1F1B18B7-3FA4-466A-8638-52819560B771

Q46851619-4AC7508E-2C7C-447E-8FD7-60A1B87DBEFA

Q46851619-67FD236B-C801-4C47-9C21-ECD31836449E

Q46851619-732215C8-2F18-41CC-8A40-41ACD428EA87

Q46851619-74442AF1-7B6E-4249-BA77-9DE3CC28C657

Q46851619-7756A7C2-992D-4F58-A090-E8909DB471EC

Q46851619-9655D3BF-F285-4329-B383-5579468D827C

Q46851619-BD3FB682-F7CA-4226-805A-02542AAB4C0B

P304

Q46851619-49E3B3D1-6046-44A5-A098-EFAC7E1A3875

P31

Q46851619-72AAA465-C13F-49C7-943D-E0471B08F6C5

P356

Q46851619-E63F51A6-BDE8-4A7C-A14A-8C0D70CF9701

P407

Q46851619-A055B1C1-071E-4713-A8A9-A916DC69E7F7

P433

Q46851619-AF2A22E8-4E89-4304-B11B-CC62494D7592

P478

Q46851619-0FE1EAF4-518F-4771-A06D-829B521E93F5

P50

Q46851619-8A0B7391-8C17-4134-AFD6-CC8B64B131C2

Q46851619-9DA13FFA-D8C4-48C8-B49C-C60248F73C8C

Q46851619-9FC45E39-F043-45AF-9D6A-597D0DB9005B

Q46851619-EDC964CB-D750-4E74-A33C-0B0FF0C5562C

P577

Q46851619-7963EC3E-C8BB-4042-8ADE-A9556B7CD332

P5875

Q46851619-B0427D82-C86F-453F-9887-AB8583DD5E3E

P698

Q46851619-A3469E9C-E27C-4469-B33D-C44D82D09331

P921

Q46851619-7A7249CD-EC31-481B-B655-9EB467549B52

Q46851619-DE95394E-5A4B-4C65-9DC1-4D5975EB2286

Q46851619-F44FFB7F-87F6-4B2E-A20F-0A9A84B84AF8

P356

J.VACCINE.2013.07.051

P1433

P1476

Construction, characterization ...... cine to enter clinical trials.

@en

P2093

Ainhoa Arbues

http://www.w3.org/2001/XMLSchema#string

Alberto Parra

http://www.w3.org/2001/XMLSchema#string

Ann Williams

http://www.w3.org/2001/XMLSchema#string

Brigitte Gicquel

http://www.w3.org/2001/XMLSchema#string

Christophe Guilhot

http://www.w3.org/2001/XMLSchema#string

Conchita Fernandez

http://www.w3.org/2001/XMLSchema#string

Dessislava Marinova

http://www.w3.org/2001/XMLSchema#string

Eugenia Puentes

http://www.w3.org/2001/XMLSchema#string

Jesus Gonzalo-Asensio

http://www.w3.org/2001/XMLSchema#string

Juan I Aguilo

http://www.w3.org/2001/XMLSchema#string

P304

4867-4873

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2013.07.051

http://www.w3.org/2001/XMLSchema#string

P407

P433

42

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Pere-Joan Cardona

Cristina Vilaplana

P577

2013-08-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256075502

http://www.w3.org/2001/XMLSchema#string

P698

23965219

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

Mycobacterium tuberculosis

attenuated vaccine